{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:30:09Z","timestamp":1777419009066,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To review the pharmacology, pharmacokinetics, adverse effects, drug interactions, dosing recommendations, and clinical efficacy of nitazoxanide, a new antiprotozoal\/anthelmintic\/antibacterial agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES<\/jats:title>\n                    <jats:p>A MEDLINE search (1966-February 2004) of both human and animal research data published in the English language was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION<\/jats:title>\n                    <jats:p>All primary and review articles pertaining to the MEDLINE search were reviewed for inclusion. Emphasis was placed on randomized, double-blind, placebo-controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS<\/jats:title>\n                    <jats:p>Nitazoxanide is approved for the treatment of giardiasis and cryptosporidiosis (first drug approved for the latter indication) in immune-competent children &lt;12 years of age. Most studies in immune-competent patients have reported clinical and parasitologic response rates close to 80% and 70%, respectively, for both indications. Response rates have been lower in immune-compromised patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Nitazoxanide should be available for patients unable to tolerate or adhere to first-line therapy employed for these intestinal protozoa. THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT ACPE UNIVERSAL PROGRAM NUMBER: 407-000-04-014-H01<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1d451","type":"journal-article","created":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T20:44:05Z","timestamp":1078173845000},"page":"634-640","source":"Crossref","is-referenced-by-count":27,"title":["Nitazoxanide Treatment for Giardiasis and Cryptosporidiosis in Children"],"prefix":"10.1177","volume":"38","author":[{"given":"Jason M","family":"Bailey","sequence":"first","affiliation":[{"name":"Jason M Bailey PharmD, Pharmacy Ambulatory Care Resident, College of Pharmacy, Idaho State University, Pocatello, ID"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Erramouspe","sequence":"additional","affiliation":[{"name":"John Erramouspe PharmD MS, Associate Professor of Pharmacy Practice, College of Pharmacy, Idaho State University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2004,4,1]]},"reference":[{"key":"bibr1-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01066.x"},{"key":"bibr2-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1086\/321008"},{"key":"bibr3-aph.1D451","first-page":"29","volume":"45","year":"2003","journal-title":"Med Lett Drugs Ther"},{"key":"bibr4-aph.1D451","volume-title":"Package insert. Alinia (nitazoxanide)","year":"2002"},{"key":"bibr5-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4922(01)02205-X"},{"key":"bibr6-aph.1D451","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2003.68.384"},{"key":"bibr7-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01419.x"},{"key":"bibr8-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(98)90974-9"},{"key":"bibr9-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.1.167-168.2000"},{"key":"bibr10-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.7.2116-2123.2002"},{"key":"bibr11-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1159\/000007200"},{"key":"bibr12-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2254-2258.2000"},{"key":"bibr13-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-002-0754-9"},{"key":"bibr14-aph.1D451","first-page":"349","volume":"34","author":"Stockis A","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"bibr15-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1086\/322038"},{"key":"bibr16-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11401-2"},{"key":"bibr17-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(98)90804-5"},{"key":"bibr18-aph.1D451","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1997.56.637"},{"key":"bibr19-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.1.114-128.2001"},{"key":"bibr20-aph.1D451","unstructured":"20.  2003 Drug topics red book. Montvale, NJ: Medical Economics, 2003."},{"key":"bibr21-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1086\/318514"},{"key":"bibr22-aph.1D451","doi-asserted-by":"publisher","DOI":"10.1086\/515352"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D451","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1D451","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:59Z","timestamp":1777374539000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1D451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1345\/aph.1D451"],"URL":"https:\/\/doi.org\/10.1345\/aph.1d451","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}